Regencell Bioscience Holdings Stock Performance
| RGC Stock | USD 5.70 0.74 11.49% |
The company holds a Beta of 1.51, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Regencell Bioscience will likely underperform. Regencell Bioscience has an expected return of -0.27%. Please make sure to check Regencell Bioscience treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Regencell Bioscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Regencell Bioscience Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (13.19) | Five Day Return 19.44 | Year To Date Return (47.33) | Ten Year Return (47.33) | All Time Return (47.33) |
1 | DCDC Has Record-Breaking Year in 2023, Highlighting 10th Anniversary | 02/13/2024 |
2 | How To Trade - Stock Traders Daily.com | 03/07/2024 |
3 | National CineMedia, Inc. Announces New 100 Million Share Repurchase Program | 03/18/2024 |
4 | Disposition of 1265 shares by Peter Brandow of Regencell Bioscience at 22.87 subject to Rule 16b-3 | 03/19/2024 |
5 | Disposition of 33006 shares by Amy Miles of Regencell Bioscience at 21.58 subject to Rule 16b-3 | 03/25/2024 |
6 | Norfolk Southern highlights strengths of its highly qualified board | 03/26/2024 |
7 | 2024 US Cannes Lions Young Lions Winners Announced | 04/18/2024 |
| Begin Period Cash Flow | 6.4 M |
Regencell |
Regencell Bioscience Relative Risk vs. Return Landscape
If you would invest 816.00 in Regencell Bioscience Holdings on January 24, 2024 and sell it today you would lose (246.00) from holding Regencell Bioscience Holdings or give up 30.15% of portfolio value over 90 days. Regencell Bioscience Holdings is generating negative expected returns assuming volatility of 8.1609% on return distribution over 90 days investment horizon. In other words, 72% of stocks are less volatile than Regencell, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Regencell Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regencell Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Regencell Bioscience Holdings, and traders can use it to determine the average amount a Regencell Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0336
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RGC |
Estimated Market Risk
| 8.16 actual daily | 72 72% of assets are less volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Regencell Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regencell Bioscience by adding Regencell Bioscience to a well-diversified portfolio.
Regencell Bioscience Fundamentals Growth
Regencell Stock prices reflect investors' perceptions of the future prospects and financial health of Regencell Bioscience, and Regencell Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regencell Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 72.66 M | ||||
| Shares Outstanding | 13.01 M | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 4.12 X | ||||
| EBITDA | (5.5 M) | ||||
| Net Income | (6.06 M) | ||||
| Cash And Equivalents | 59.41 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 463.67 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 13.94 X | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (4.96 M) | ||||
| Earnings Per Share | (0.45) X | ||||
| Market Capitalization | 83.8 M | ||||
| Total Asset | 12.62 M | ||||
| Retained Earnings | (17.32 M) | ||||
| Working Capital | 11.01 M | ||||
| Current Asset | 438.2 M | ||||
| Current Liabilities | 551.3 M | ||||
About Regencell Bioscience Performance
To evaluate Regencell Bioscience Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Regencell Bioscience generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Regencell Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Regencell Bioscience market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Regencell's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 67.96 | 71.35 | |
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.12 | 0.12 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | (0.13) | (0.14) |
Things to note about Regencell Bioscience performance evaluation
Checking the ongoing alerts about Regencell Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Regencell Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regencell Bioscience generated a negative expected return over the last 90 days | |
| Regencell Bioscience has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (6.06 M) with profit before taxes, overhead, and interest of 0. | |
| Regencell Bioscience Holdings has about 59.41 K in cash with (4.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Regencell Bioscience has a poor financial position based on the latest SEC disclosures | |
| Roughly 89.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from businesswire.com: 2024 US Cannes Lions Young Lions Winners Announced |
- Analyzing Regencell Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regencell Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Regencell Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regencell Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regencell Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regencell Bioscience's stock. These opinions can provide insight into Regencell Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.